Cell cycle gene regulation in reversibly differentiated new human hepatoma cell lines.
Several novel differentiated cell lines have been derived from a human hepatocarcinoma named HBG. Analysis of their functional properties evidenced a gradual differentiation process as they became confluent and a remarkable stability of the whole quiescent population for at least 6 weeks. However, when replated at low density after several weeks of quiescence, the differentiated cells were able to rapidly reverse to active proliferation, accompanied by transient dedifferentiation. Demonstration that the differentiated hepatic cells were growth-arrested in G1 phase was provided by the increased number of cells with 2C DNA content and decreased expression of S-phase markers. Characteristic features of oncogenes and cell cycle genes were defined during the differentiation process: (a) a biphasic expression of c-myc, with the latter wave covering the quiescence period; (b) opposite kinetics of c-Ki-ras and of N-ras expression with a pattern of changes paralleling that of c-myc; and (c) a decrease of cyclin D1 protein expression and of the cyclin D1-associated kinase activity. The mechanisms by which quiescent differentiated cells might reinitiate active proliferation were analyzed by studying several genes involved in cell growth and death regulation. We found: (a) a point mutation and loss of the specific activity of the tumor suppressor gene p53 without alteration of the apoptotic response to transforming growth factor beta1; (b) a gradual decrease of retinoblastoma protein, which was constantly present, mainly in a hyperphosphorylated form; and (c) an increase of cyclin-dependent kinase inhibitor p27 expression in confluent differentiating cells, as expected, whereas, surprisingly, a disappearance of the p21 protein was observed in parallel. These data may reflect specific mechanisms of cell cycle regulation in liver parenchymal cells through which these cells can proceed to control their reversible differentiation program.
Glaise
D
D
INSERM U49, Hôpital Pontchaillou, Rennes, France.
Ilyin
G P
GP
Loyer
P
P
Cariou
S
S
Bilodeau
M
M
Lucas
J
J
Puisieux
A
A
Ozturk
M
M
Guguen-Guillouzo
C
C
D000818:Animals; D017209:Apoptosis; D016203:CDC2 Protein Kinase / Q000235:genetics; D006528:Carcinoma, Hepatocellular / Q000473:pathology; D002453:Cell Cycle / Q000235:genetics*; D002454:Cell Differentiation; D002455:Cell Division; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D016213:Cyclins / Q000235:genetics; D004791:Enzyme Inhibitors; D016193:G1 Phase; D005786:Gene Expression Regulation; D016161:Genes, Retinoblastoma; D018816:Genes, cdc; D016259:Genes, myc; D016158:Genes, p53; D006801:Humans; D008099:Liver / Q000166:cytology* / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D009154:Mutation; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D016213:Cyclins; D004791:Enzyme Inhibitors; D016212:Transforming Growth Factor beta; D016203:CDC2 Protein Kinase; D018844:Cyclin-Dependent Kinases